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A B S T R A C T
Background: Rheumatic mitral stenosis constitutes a major cause of acquired heart disease complicating
pregnancy in India. In the present study, we have studied the fetal and maternal outcomes of women
undergoing balloon mitral valvotomy during pregnancy.
Methods and results: 49 pregnant ladies were included in this study in whom balloon mitral valvotomy
was performed. The mean age of these patients was 25.7  3.1 years. The mean gestational age was
23.5  5.2 weeks (12–36 weeks). The procedure was successful in 48 patients (95.9%). Mean two-
dimensional MVA increased from baseline value of 0.93  0.17 cm2 to 1.75  0.27 cm2 (p value <0.0001).
Pre-procedure peak pulmonary artery pressure was 43.05  15.88 mmHg, which decreased to
22.31  6.36 mmHg (p value <0.0001). Hemodynamic data showed pre-BMV left atrial mean pressure of
29.6  6.6 mmHg, which decreased to 13.7  4.8 mmHg after the procedure (p value <0.0001). Mean
ﬂuoroscopy time was 6.4  1.2 min. There was no maternal mortality in our study. One procedure had to be
abandoned, because of failed septal puncture. One of the patients developed cardiac tamponade and another
patient developed severe mitral regurgitation, which were managed medically. The patient who developed
severe mitral regurgitation later underwent mitral valve replacement. Post-procedure follow-up showed an
improvement in NYHA status by at least one class in 81.3% of patients. Thirty-nine (81.3%) patients had a term
normal vaginal delivery and 8 (16.7%) underwent cesarean section for obstetric indications. One of the
patients had abortion on the second day of the procedure.
Conclusion: Percutaneous mitral valvotomy during pregnancy is safe and provides excellent
symptomatic relief and hemodynamic improvement. This should be considered as the treatment of
choice when managing pregnant women with severe mitral stenosis.
 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Rheumatic mitral stenosis constitutes a major cause of acquired
heart disease complicating pregnancy in India.1 Symptomatic
worsening occurs during pregnancy because of increased hemo-
dynamic burden associated with pregnancy, which includes
increased blood volume, heart rate, mean left atrial pressure,
and pulmonary venous pressure which can precipitate pulmonary
edema.2–5 Medical treatment alone may not be sufﬁcient in these
patients and relief of mitral obstruction is often required. Treating
these patients with surgical valvotomy has shown to have adverse* Corresponding author at: Department of Cardiology, Government Medical
College, Kozhikode, Kerala 673008, India. Tel.: +91 9847015011.
E-mail address: vinayakumard@gmail.com (D. Vinayakumar).
http://dx.doi.org/10.1016/j.ihj.2016.04.017
0019-4832/ 2016 Cardiological Society of India. Published by Elsevier B.V. This is an
licenses/by-nc-nd/4.0/).fetal outcomes.7–10 Balloon mitral valvotomy (BMV)6 is an
alternative option in this situation. In the present study, we have
examined the fetal and maternal outcomes of women undergoing
BMV during pregnancy.
2. Methods
Data were collected prospectively on the fetal and maternal
outcomes in pregnant women undergoing BMV for symptomatic
mitral stenosis, between 1998 and 2013. Patients with severe
mitral stenosis on echocardiographic evaluation were planned for
BMV. The criteria were:
 Two-dimensional echocardiography (2D ECHO) mitral valve area
(MVA) by planimetry 1.0 cm2 open access article under the CC BY-NC-ND license (http://creativecommons.org/
Table 2
Echocardiographic and hemodynamic data before and after BMV.
Pre-BMV (mean  SD) Post-BMV (mean  SD)
2D MVA 0.93  0.17 cm2 1.75  0.27 cm2
LA mean pressure 29.57  6.55 mmHg 13.68  4.77 mmHg
PAP 43.05  15.88 mmHg 22.31  6.36 mmHg
NYHA class II–IV (2.5  0.6) I–II (1  0.5)
Peak mitral valve gradient 26.22  5.95 mmHg 10.4  3.42 mmHg
BMV, balloon mitral valvotomy; LA, left atrium; PAP, peak pulmonary artery
pressure; SD, standard deviation.
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 Resting pulmonary artery systolic pressure >50 mmHg.
Patients with symptomatic mitral stenosis and mitral valve area
between 1 and 1.5 cm2 were also included.
Patients with more than mild mitral regurgitation (moderate
mitral regurgitation) and left atrial/left atrial appendage clot were
excluded.
Full clinical evaluation was done in all patients by assessing
functional class, pliability of the mitral valve, and presence of
audible mitral regurgitation. All the included patients underwent a
comprehensive transthoracic echocardiographic evaluation. As-
sessment of the mitral valve was done with special attention to the
mitral valve morphology, commissural calciﬁcation, severity of
subvalvar pathology, and severity of mitral regurgitation to
determine the suitability for BMV. Mitral valve area was assessed
by planimetry using standard technique. Transmitral gradient and
peak pulmonary artery pressures were assessed using Doppler
technique. Left atrial mean pressure and transmitral gradient were
recorded before and after balloon dilatation.
Two-dimensional and color Doppler echocardiography was
performed within 24 h after the procedure to assess the 2D MVA by
planimetry, transmitral gradient, severity of mitral regurgitation,
and peak pulmonary artery pressure. (Within 24 h post-procedure,
2D MVA was calculated by planimetry and transmitral gradient,
severity of mitral regurgitation, and peak pulmonary artery
pressure estimated using Doppler echocardiography.) The proce-
dure was considered successful when
 there was more than 50% increase in 2D MVA from baseline
 no signiﬁcant post-procedural increase in mitral regurgitation
with an absolute 2D MVA greater than 1.5 cm2.
The symptomatic statuses of the patients were also assessed
post-procedure. Patients were followed up for one year and regular
antenatal evaluation was advised including ultrasonography for
assessment of fetal growth. Cesarean section was advised for any
obstetric indication. Clinical and echocardiographic evaluation was
repeated post-delivery.
2.1. Statistical analysis
All data were expressed as mean (standard deviation, SD). The
pre- and post-BMV data were compared using t test. A p value of
<0.05 was considered statistically signiﬁcant.
3. Results
There were 49 patients during the period who qualiﬁed for
BMV. Baseline characteristics are shown in Table 1. Mean age
of the patient was 25.7  3.1 years. Mean gestational age was
23.5  5.2 weeks (12–36 weeks). One patient had to be included at
36th week of gestation as she presented for the ﬁrst time in the third
trimester. Another patient at 12 weeks of gestation was includedTable 1
Baseline characteristics of pregnant women who underwent BMV (n = 49).
Age 25.69  3.08 (21–33)
Gestational age at which BMV is performed 23.5  5.2 weeks
NYHA class
II 24 (50%)
III 22 (45%)
IV 2 (4.0%)
2D MVA 0.93  0.17 cm2
Atrial ﬁbrillation 14 (28.5%)
BMV, balloon mitral valvotomy; MVA, mitral valve area.because she presented with class III symptoms, orthopnea and PND in
spite of optimal medication. Symptomatic status varied from New
York Heart Association (NYHA) functional class II–IV (mean
2.5  0.6). Sinus rhythm was noted in 35 (71.43%) of the patients.
Fourteen patients (28.57%) had atrial ﬁbrillation. The procedure was
successful in 48 patients. Mean two-dimensional MVA increased from
baseline value of 0.93  0.17 cm2 to 1.75  0.27 cm2 (p value
<0.0001). The pre-procedural peak pulmonary arterial pressure
(43.05  15.88 mmHg) decreased to 22.31  6.36 mmHg (p value
<0.0001). Pre-BMV peak mitral valve gradient assessed by Doppler
echocardiography was 26.22  5.95. Based on hemodynamic data,
it was found that the pre-BMV left atrial mean pressure
(29.6  6.6 mmHg), reduced to 13.7  4.8 mmHg after the procedure
(p value <0.0001). Table 2 shows the pre-BMV and post-BMV
comparison. The mean ﬂuoroscopy time was 6.4  1.2 min. There was
no maternal mortality in this study. The procedure was successfully
completed in 48 patients (95.9%); one procedure had to be
abandoned, because of failure to puncture the septum due to marked
bulge of the inter atrial septum. This patient had to undergo surgical
valvotomy. Cardiac tamponade developed in a patient who under-
went a successful valvotomy, and it necessitated a surgical repair of
the rent. This patient went on to have a term normal delivery. One
patient who developed severe mitral regurgitation was managed
medically since she was hemodynamically and symptomatically
stable and she also had a normal vaginal delivery subsequently. This
patient underwent elective mitral valve replacement later. Post-
procedure follow-up showed an improvement in NYHA status by at
least one class in 81.3% of patients.
Thirty-nine (81.3%) patients had a term normal vaginal delivery
and eight (16.7%) had cesarean section for obstetric indications.
One patient had an abortion on the second day post-procedure.
4. Discussion
Rheumatic mitral stenosis is the most common cardiovascu-
lar disease complicating pregnancy in developing countries.
Marked hemodynamic changes and the increased cardiac output
have their adverse effects during pregnancy, and can lead to
worsening of symptoms by approximately 30 weeks of gestation,
during labor and after delivery. Maternal mortality is approxi-
mately 1% in untreated patients and depends on the functional
class of patients during pregnancy. Studies have shown that
open surgical procedures during pregnancy carry an adverse
fetal and maternal outcome. Medical management alone does
not give adequate symptomatic relief or prevent an adverse
outcome. In this context, BMV performed during pregnancy is
found to be safe and provides excellent symptomatic relief. In a
study conducted by Mishra et al.11 in All India Institute of
Medical Sciences, India (n = 85), a success rate of 94.1% was
noted when BMV was performed in severe mitral stenosis
patients of NYHA class III–IV, at a mean gestational age of
24.84  4 weeks. In the present study, majority of patients were
in NYHA functional class II–III and the success rate was 98%.
In both groups, patients had excellent symptomatic relief and
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both the studies. Singh et al.12 from Jayadeva Institute of
Cardiovascular Research, Bengaluru, India studied outcome in
58 pregnant patients with mean gestational age of 26.53  5.2
weeks. They reported a success rate of 91% and increase in mean
2D MVA from 0.87  0.14 cm2 to 1.82  0.25 cm2. No maternal
mortality or abortion occurred during this study. Harikrishnan
et al.13 (n = 36) reported a procedural success rate of 97.2% and an
excellent symptomatic improvement. There was no maternal
mortality in this study, though 3 preterm deliveries were reported.
In the present series, 39 (79.3%) patients had term normal vaginal
deliveries and 8 (16.7%) had caesarian sections. The mean
ﬂuoroscopy time in the study of Harikrishnan et al. was
5.4  5.8 min which were comparable to the present study. Gupta
et al.14 evaluated the safety and efﬁcacy of BMV in 40 pregnant
women with rheumatic mitral stenosis. Thirty-nine patients
underwent a successful procedure. Eleven patients in whom
BMV was performed before 20 weeks of gestation underwent
medical termination of pregnancy. Out of the 29 women who
continued pregnancy, one patient developed preterm labor and one
had a stillbirth. There was no maternal mortality in this study.
Mean ﬂuoroscopy time was 7.8  1.8 min. Routray et al. have
studied patients undergoing BMV during pregnancy and the long-
term effects on child development in them.15 They performed BMV
in 40 pregnant women and 39 of them had successful outcome.
After a mean follow-up of 36  15 months, 38 babies maintained
normal growth and development except for a single death of a
baby at 7th month due to pneumonia. Kinsara16 conducted a
follow-up study in 20 pregnant women who had BMV during
pregnancy. Their offspring had mean age of 63  39 months (range
6–98). All had normal growth and development as assessed by
standard development charts and laboratory tests. The above
studies show that BMV done during pregnancy had no major
adverse effects on the fetus and postnatal growth and development
of the offspring.
In the present study, out of 49 patients, 47 had a successful
procedure with mean ﬂuoroscopy time of 6.44  1.16 min. There
were no preterm delivery, but there was an abortion following the
procedure. We found excellent symptomatic relief following the
procedure without an increased risk of maternal mortality. These
results are consistent with previous studies and show that perform-
ing BMV during pregnancy in symptomatic mitral stenosis patients is
safe and effective with good fetal and maternal outcomes.5. Conclusion
Percutaneous mitral valvotomy during pregnancy is safe and
provides excellent symptomatic relief and hemodynamic im-
provement. This should be considered as the treatment of choice
when managing pregnant women with severe mitral stenosis.
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